logo
login
Login
Services
Services
About master page
About
News
News
Contact
Contact
EN

LANDMARK TAILORx RESULTS

The long-awaited results of the Trial Assigning Individualized Options for Treatment (TAILORx) definitively identified a vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.

TAILORx can establish the Oncotype DX test as definitive standard of care

Know with confidence who will benefit from chemotherapy and who will not.

TAILORx results eliminate uncertainty around intermediate scores and show that most patients do not benefit from chemotherapy.

TAILORx Who Benefits

IMPROVING OUTCOMES OVERALL

Adjuvant chemotherapy may now be guided with an unprecedented level of evidence and precision using the Oncotype DX test to identify:

  • the vast majority of patients with no chemotherapy benefit
  • the important minority for whom chemotherapy may be life-saving

TAILORx shows that clinical risk features alone are not sufficient to determine chemotherapy benefit.


73% of patients with high clinical risk* had Recurrence Score results 0-25 and may have been overtreated without the Recurrence Score result**

*High clinical risk: Grade 1, >3 cm; Grade 2, >2 cm; Grade 3, >1 cm.
**Based on the primary analysis of TAILORx study

43% of patients with Recurrence Score results 26-100 had low clinical risk*** and may have been undertreated without the Recurrence Score result

***Low clinical risk: Grade 1, ≤3 cm; Grade 2, ≤2 cm; Grade 3, ≤1 cm.

The largest randomized adjuvant breast cancer treatment trial ever conducted


TAILORx was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute. Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.

Read the article on NEJM

Map

Change cookies consent Revoke cookies consent